In the relentless pursuit of therapeutic innovation, where drug candidate attrition exceeds 90%, the integration of computational tools into medicinal chemistry is both a necessity and a challenge. The recent publication, “AI-Driven Optimization of Small Molecule ADMET Profiles” (A2025, J. Med. Chem., 2025, hypothetical), seeks to advance this paradigm by
I’m used to navigating uncharted waters—whether it’s optimizing a lead compound or diving into La Jolla’s kelp forests. But nothing quite matches the rush of surfing Oceanside, California, where the waves form liquid caverns begging for barrel rides and the skies beckon for airs. Oceanside’s
In the high-stakes arena of drug discovery, where the attrition rate of drug candidates exceeds 90%, medicinal chemists face immense pressure to deliver molecules that are not only potent but also safe and bioavailable. As a biotech entrepreneur leading a team developing novel therapeutics, I have witnessed firsthand the critical
As a founder, my days are a whirlwind of data, decisions, and deadlines. Between pitching investors, troubleshooting experiments, and sneaking in a spearfishing dive off La Jolla, my brain rarely gets a break. That’s why I turned to deprivation tanks—those futuristic pods of saltwater that promise to unplug
As a biotech founder, I’m used to chasing breakthroughs in the lab, but there’s another kind of alchemy I’m obsessed with: composing post-rock music in drop D tuning. It’s my escape, my canvas, and my way of making sense of the world. Post-rock—those sprawling, instrumental
There’s something primal about slipping beneath the waves, speargun in hand, and gliding through the towering kelp forests of La Jolla. It’s not just fishing—it’s a hunt, a meditation, and a humbling reminder of nature’s complexity, all rolled into one. As a biotech founder, I
If you’re in biotech, you know the valley of death isn’t just a catchy phrase—it’s a brutal reality. It’s that make-or-break stretch where your brilliant idea, backed by years of lab work, either secures the funding and momentum to reach the clinic or crashes and
I’ve always been a sucker for the hustle. The thrill of building something from nothing, watching metrics climb, and seeing a vision take shape—it’s intoxicating. But if there’s one lesson I’ve learned (the hard way, naturally), it’s that scaling up isn’t always the
Welcome to Intermolecular Ambitions—my corner of the internet where science, entrepreneurship, and the pursuit of meaning converge. As a biotech founder navigating the exhilarating chaos of drug discovery, I’ve learned that breakthroughs don’t just happen in the lab. They spark at the intersection of rigorous science, bold